This is a highly risky play by the state-owned Rosnano. It is good that the shareholders are unlikely to sue the management.
http://www.fiercebiotech.com/story/domain-partners-rusnano-760m-biotech-investment-plan/2012-03-06However, from Western perspective, it's worth checking the protection and integrity of the intellectual property sold to the Russian side.
Russia's pharma sector is decades behind the West and has a hard time coping with Western manufacturing standards and clinical trial protocols.
Nevertheless, even if some of this biotech investment succeeds, this will be a boon for Chubais, for Rosnano, and for Russia.
Domain partners with RusNano on $760M biotech investment plan